Telavancin Pharmacokinetics in Cystic Fibrosis Patients
Status:
Completed
Trial end date:
2019-04-17
Target enrollment:
Participant gender:
Summary
Due to emerging resistance, new antibiotic options are needed to treat CF acute pulmonary
exacerbations caused by methicillin resistant Staphylococcus aureus (MRSA). There is
established evidence that adult patients with cystic fibrosis (CF) may have altered
antibiotic pharmacokinetics compared with non-CF patients. Telavancin is a lipoglycopeptide
antibiotic that has activity against gram-positive bacteria including MRSA. This study will
determine the pharmacokinetics and tolerability of telavancin in 18 adult CF patients
admitted for a pulmonary exacerbation at 1 of 4 participating hospitals in the US.
Phase:
Phase 4
Details
Lead Sponsor:
Joseph Kuti Joseph L. Kuti, PharmD
Collaborators:
Cumberland Pharmaceuticals, Inc. Theravance Biopharma, US, Inc.